BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

With a combination of genomic surveillance and in vitro laboratory assays, COVID-19 drug developers have the tools to get an early read on the vulnerability of their candidates to viral variants and course...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

A controversy over a memo from HHS Secretary Alex Azar has further exposed the fraught atmosphere in Washington over claims that FDA and other agencies have been politicized amid the global pandemic. In the latest BioCentury This...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for cancer....
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

Leaders of Operation Warp Speed and Trump administration officials Wednesday morning released plans for the distribution of hundreds of millions of doses of COVID-19 vaccines, outlined how access will be prioritized in the case of...
BioCentury | Sep 9, 2020
Politics & Policy

Impact of China’s export restrictions on biopharma dealmaking likely limited, at least for now

While a handful of revisions to China’s export restrictions apply to technologies in the biopharma sector, their effect on cross-border dealmaking is likely limited given that many domestic companies are built on an in-licensing rather...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
Items per page:
1 - 10 of 1665
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

With a combination of genomic surveillance and in vitro laboratory assays, COVID-19 drug developers have the tools to get an early read on the vulnerability of their candidates to viral variants and course...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

A controversy over a memo from HHS Secretary Alex Azar has further exposed the fraught atmosphere in Washington over claims that FDA and other agencies have been politicized amid the global pandemic. In the latest BioCentury This...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for cancer....
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

Leaders of Operation Warp Speed and Trump administration officials Wednesday morning released plans for the distribution of hundreds of millions of doses of COVID-19 vaccines, outlined how access will be prioritized in the case of...
BioCentury | Sep 9, 2020
Politics & Policy

Impact of China’s export restrictions on biopharma dealmaking likely limited, at least for now

While a handful of revisions to China’s export restrictions apply to technologies in the biopharma sector, their effect on cross-border dealmaking is likely limited given that many domestic companies are built on an in-licensing rather...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
Items per page:
1 - 10 of 1665